Loading...
Nova Mentis Life Science Corp.
NMLSF•PNK
Healthcare
Biotechnology
$0.07
$-0.03(-27.77%)

Over the past four quarters, Nova Mentis Life Science Corp. demonstrated steady revenue growth, increasing from -$28346.00 in Q4 2023 to $0.00 in Q3 2024. Operating income reached $0.00 in Q3 2024, maintaining a consistent N/A margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$122885.00, reflecting operational efficiency. Net income rose to $459566.00, with EPS at $0.02. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan